How is AI changing drug discovery in the UK?

AI is reshaping drug discovery in the UK, but success depends on pairing algorithms with human expertise rather than replacing it. Dan Jamieson of Biorelate notes that AI-first companies developing drugs independently have yet to pass a phase two trial [#420], whereas established pharma and biotech firms are seeing better results when domain experts use AI to accelerate specific stages of discovery [#420]. The technology's real value lies in connecting previously siloed teams across target selection, validation, and later-stage development, giving researchers visibility across the entire process [#420].

The current hype around AI drug discovery attracts capital and talent partly because margins are attractive to investors [#304], but the practical gains are narrower than the buzz suggests. Work on problems like antibiotic resistance shows promise [#330], and companies like Exscientia have demonstrated the approach works when human chemists and data scientists collaborate effectively [Ep 49]. The winners won't be pure-play AI platforms, but organisations that combine computational insight with experienced drug hunters who know what a discovery candidate actually needs to become a medicine.